Pharmacogenetics: potential role in the treatment of diabetes and obesity
Open accessAbstract
BACKGROUND: Common genetic variation is associated with increased risk of common metabolic diseases such as type 1 and type 2 diabetes, and obesity. Increasing experience with genetic association studies has led to an understanding of the large sample sizes required to detect a weak to moderate genetic predisposition to disease, the need to reproduce such associations in independent cohorts, and the statistical criteria required to detect a true association. This approach has been used successfully to identify disease-associated gene variation usually in representative populations of large numbers. OBJECTIVE: To review the current understanding of how common genetic variation influences predisposition to, and treatment of, metabolic disease. METHODOLOGY: Review of scientific literature. RESULTS: While there has been progress in understanding how genetic variation predisposes to diabetes and obesity, and how candidate genes may alter drug response, several caveats limit the interpretation and significance of pharmacogenetic studies published to date: those caveats typically include relatively small numbers of participants and choice of endpoints in determining gene-associated differences in response, which may not be clinically significant or relevant as a biomarker or predictor of a desired clinical effect. The genetic variants studied at a given locus are often limited in number and may not represent a comprehensive map of the region under study. CONCLUSIONS: The pharmacogenetic associations in diabetes and obesity that have been reported to date have had limited impact on the choice of individual treatments. We perceive, however, that this field is in its infancy in these multifactorial metabolic diseases, and with further advances and future drug intervention trials designed in a way that allows a more clear interpretation of the impact of genetic variation on differences in drug response in obesity and diabetes, it is anticipated that pharmacogenetics will have a significant impact on individualizing medical care.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
There is interindividual heterogeneity in response to GLP-1.
“However, there has been some suggestion that there is interindividual heterogeneity in response to GLP-1, raising the possibility that some individuals may benefit more from such therapy than others earlier in the disease (25, 31).”
From A model of GLP-1 action on insulin secretion in nondiabetic subjects (2010) · cites this paper as [31]
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667 · see citing works
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419 · see citing works
Lesch, K.-P., Bengel, D., Heils, A., Sabol, S. Z., Greenberg, B. D., Petri, S., Benjamin, J., Müller, C. R., Hamer, D. H., & Murphy, D. L. (1996) · Science · doi:10.1126/science.274.5292.1527 · Cited by 5,162 · see citing works
Frayling, T. M., Timpson, N. J., Weedon, M. N., Zeggini, E., Freathy, R. M., Lindgren, C. M., Perry, J. R. B., Elliott, K. S., Lango, H., Rayner, N. W., et al. (2007) · Science · doi:10.1126/science.1141634 · Cited by 4,531 · see citing works
A genome-wide association study identifies novel risk loci for type 2 diabetes
Sladek, R., Rocheleau, G., Rung, J., Dina, C., Shen, L., Serre, D., Boutin, P., Vincent, D., Belisle, A., Hadjadj, S., et al. (2007) · Nature · doi:10.1038/nature05616 · Cited by 2,993 · see citing works
Genome-wide association studies for common diseases and complex traits
Hirschhorn, J. N., & Daly, M. J. (2005) · Nature Reviews Genetics · doi:10.1038/nrg1521 · Cited by 2,853 · see citing works
Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels
Saxena, R., Voight, B. F., Lyssenko, V., Burtt, N. P., de Bakker, P. I. W., Chen, H., Roix, J. J., Kathiresan, S., Hirschhorn, J. N., Daly, M. J., et al. (2007) · Science · doi:10.1126/science.1142358 · Cited by 2,843 · see citing works
A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants
Scott, L. J., Mohlke, K. L., Bonnycastle, L. L., Willer, C. J., Li, Y., Duren, W. L., Erdos, M. R., Stringham, H. M., Chines, P. S., Jackson, A. U., et al. (2007) · Science · doi:10.1126/science.1142382 · Cited by 2,753 · see citing works
Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes
Grant, S. F. A., Thorleifsson, G., Reynisdottir, I., Benediktsson, R., Manolescu, A., Sainz, J., Helgason, A., Stefansson, H., Emilsson, V., Helgadottir, A., et al. (2006) · Nature Genetics · doi:10.1038/ng1732 · Cited by 2,287 · see citing works
Replication of Genome-Wide Association Signals in UK Samples Reveals Risk Loci for Type 2 Diabetes
Zeggini, E., Weedon, M. N., Lindgren, C. M., Frayling, T. M., Elliott, K. S., Lango, H., Timpson, N. J., Perry, J. R. B., Rayner, N. W., Freathy, R. M., et al. (2007) · Science · doi:10.1126/science.1142364 · Cited by 2,194 · see citing works
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease
Ueda, H., Howson, J. M. M., Esposito, L., Heward, J., Snook, Chamberlain, G., Rainbow, D. B., Hunter, K. M. D., Smith, A. N., Di Genova, G., et al. (2003) · Nature · doi:10.1038/nature01621 · Cited by 2,175 · see citing works
Effects of Recombinant Leptin Therapy in a Child with Congenital Leptin Deficiency
Farooqi, I. S., Jebb, S. A., Langmack, G., Lawrence, E., Cheetham, C. H., Prentice, A. M., Hughes, I. A., McCamish, M. A., & O'Rahilly, S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909163411204 · Cited by 1,998 · see citing works
The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S.-H., Bardeesy, N., DePinho, R. A., Montminy, M., & Cantley, L. C. (2005) · Science · doi:10.1126/science.1120781 · Cited by 1,950 · see citing works
The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes
Altshuler, D., Hirschhorn, J. N., Klannemark, M., Lindgren, C. M., Vohl, M.-C., Nemesh, J., Lane, C. R., Schaffner, S. F., Bolk, S., Brewer, C., et al. (2000) · Nature Genetics · doi:10.1038/79216 · Cited by 1,766 · see citing works
Scuteri, A., Sanna, S., Chen, W.-M., Uda, M., Albai, G., Strait, J., Najjar, S., Nagaraja, R., Orrú, M., Usala, G., et al. (2007) · PLoS Genetics · doi:10.1371/journal.pgen.0030115 · Cited by 1,724 · see citing works
Variation in FTO contributes to childhood obesity and severe adult obesity
Christian Dina, C., Meyre, D., Gallina, S., Durand, E., Körner, A., Jacobson, P., Carlsson, L. M. S., Kieß, W., Vatin, V., Lecœur, C., et al. (2007) · Nature Genetics · doi:10.1038/ng2048 · Cited by 1,620 · see citing works
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · see citing works
Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes
Finland, G. O. T. 1. D. I., Todd, J. A., the Wellcome Trust Case Control Consortium, Walker, N. M., Cooper, J. D., Smyth, D. J., Downes, K., Plagnol, V., Bailey, R., Nejentsev, S., et al. (2007) · Nature Genetics · doi:10.1038/ng2068 · Cited by 1,456 · see citing works
Self-citationHeymsfield, S. B., Greenberg, A. S., Fujioka, K., Dixon, R. M., Kushner, R., Hunt, T., Lubina, J. A., Patane, J., Self, B., Hunt, P., et al. (1999) · JAMA · doi:10.1001/jama.282.16.1568 · Cited by 1,422 · see citing works
A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes
Bottini, N., Musumeci, L., Alonso, A., Rahmouni, S., Nika, K., Rostamkhani, M., MacMurray, J. P., Meloni, T., Lucarelli, P., Pellecchia, M., et al. (2004) · Nature Genetics · doi:10.1038/ng1323 · Cited by 1,419 · see citing works
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
Després, J.-P., Golay, A., & Sjöström, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044537 · Cited by 1,392 · see citing works
A variant in CDKAL1 influences insulin response and risk of type 2 diabetes
Steinthorsdottir, V., Thorleifsson, G., Reynisdottir, I., Benediktsson, R., Jonsdottir, T., Walters, G. B., Styrkarsdottir, U., Gretarsdottir, S., Emilsson, V., Ghosh, S., et al. (2007) · Nature Genetics · doi:10.1038/ng2043 · Cited by 1,072 · see citing works
Kieffer, T. J., & Habener, J. F. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,056 · see citing works
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations
Pearson, E. R., Flechtner, I., Njølstad, P. R., Malecki, M. T., Flanagan, S. E., Larkin, B., Ashcroft, F. M., Klimes, I., Codner, E., Iotova, V., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061759 · Cited by 988 · see citing works
Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action
Shu, Y., Sheardown, S. A., Brown, C., Owen, R., Zhang, S., Castro, R. A., Ianculescu, A. G., Lin, Y., Lo, J. C.-M., Burchard, E. G., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30558 · Cited by 963 · see citing works
TCF7L2 Polymorphisms and Progression to Diabetes in the Diabetes Prevention Program
Florez, J. C., Jablonski, K. A., Bayley, N., Pollin, T. I., de Bakker, P. I. W., Shuldiner, A. R., Knowler, W. C., Nathan, D. M., & Altshuler, D. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062418 · Cited by 834 · see citing works
Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes
Lyssenko, V., Lupi, R., Marchetti, P., Guerra, S. D., Orho‐Melander, M., Almgren, P., Sjögren, M., Ling, C., Eriksson, K., Lethagen, Υ.-L., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30706 · Cited by 821 · see citing works
Altshuler, D., Daly, M. J., & Kruglyak, L. (2000) · Nature Genetics · doi:10.1038/79839 · Cited by 762 · see citing works
Gloyn, A. L., Weedon, M. N., Owen, K. R., Turner, M. J., Knight, B. A., Hitman, G., Walker, M., Levy, J. C., Sampson, M., Halford, S., et al. (2003) · Diabetes · doi:10.2337/diabetes.52.2.568 · Cited by 754 · see citing works
Gudmundsson, J., Sulem, P., Steinthorsdottir, V., Bergthorsson, J. T., Thorleifsson, G., Manolescu, A., Rafnar, T., Gudbjartsson, D., Agnarsson, B. A., Baker, A., et al. (2007) · Nature Genetics · doi:10.1038/ng2062 · Cited by 723 · see citing works
Therapeutic roles of peroxisome proliferator-activated receptor agonists
Staels, B., & Fruchart, J.-C. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2460 · Cited by 646 · see citing works
Farooqi, I. S., & O’Rahilly, S. (2006) · Endocrine Reviews · doi:10.1210/er.2006-0040 · Cited by 583 · see citing works
Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution
Helgason, A., Pálsson, S., Þorleifsson, G., Grant, S. F. A., Emilsson, V., Gunnarsdottir, S., Adeyemo, A., Chen, Y., Chen, G., Reynisdóttir, I., et al. (2007) · Nature Genetics · doi:10.1038/ng1960 · Cited by 520 · see citing works
Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin
Wang, D.-S., Jonker, J. W., Kato, Y., Kusuhara, H., Schinkel, A. H., & Sugiyama, Y. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.034140 · Cited by 441 · see citing works
Lowe, C. E., Cooper, J. D., Brusko, T. M., Walker, N. M., Smyth, D. J., Bailey, R., Bourget, K., Plagnol, V., Field, S., Atkinson, M. A., et al. (2007) · Nature Genetics · doi:10.1038/ng2102 · Cited by 427 · see citing works
Yi, F., Brubaker, P. L., & Jin, T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m411487200 · Cited by 413 · see citing works
Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges
Wilke, R. A., Lin, D. W., Roden, D. M., Watkins, P. B., Flockhart, D. A., Zineh, I., Giacomini, K. M., & Krauss, R. M. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2423 · Cited by 394 · see citing works
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-3-199802010-00001 · Cited by 385 · see citing works
Common variants in WFS1 confer risk of type 2 diabetes
Sandhu, M. S., Weedon, M. N., Fawcett, K. A., Wasson, J., Debenham, S. L., Daly, A., Allen, H. L., Frayling, T. M., Neumann, R. J., Sherva, R., et al. (2007) · Nature Genetics · doi:10.1038/ng2067 · Cited by 378 · see citing works
Interaction of Nuclear Receptors with the Wnt/β-Catenin/Tcf Signaling Axis: Wnt You Like to Know?
Mulholland, D. J., Dedhar, S., Coetzee, G. A., & Nelson, C. C. (2005) · Endocrine Reviews · doi:10.1210/er.2003-0034 · Cited by 377 · see citing works
Saxena, R., Gianniny, L., Burtt, N. P., Lyssenko, V., Giuducci, C., Sjögren, M., Florez, J. C., Almgren, P., Isomaa, B., Orho‐Melander, M., et al. (2006) · Diabetes · doi:10.2337/db06-0381 · Cited by 373 · see citing works
Vella, A. V., Cooper, J. D., Lowe, C. E., Walker, N. M., Nutland, S. L., Widmer, B., Jones, R. W., Ring, S. M., McArdle, W. L., Pembrey, M. E., et al. (2005) · The American Journal of Human Genetics · doi:10.1086/429843 · Cited by 352 · see citing works
Self-citationFuhlendorff, J., Rorsman, P., Kofod, H., Brand, C. L., Rolin, B., MacKay, P., Shymko, R., & Carr, R. D. (1998) · Diabetes · doi:10.2337/diabetes.47.3.345 · Cited by 310 · see citing works
Efficacy and Safety of Troglitazone in the Treatment of Lipodystrophy Syndromes
Arioglu, E., Duncan-Morin, J., Sebring, N., Rother, K. I., Gottlieb, N., Lieberman, J., Herion, D., Kleiner, D. E., Reynolds, J., Premkumar, A., et al. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-4-200008150-00009 · Cited by 303 · see citing works
Damcott, C., Pollin, T. I., Reinhart, L. J., Ott, S. H., Shen, H., Silver, K. D., Mitchell, B. D., & Shuldiner, A. R. (2006) · Diabetes · doi:10.2337/db06-0338 · Cited by 276 · see citing works
The Efficacy and Safety of Sibutramine for Weight Loss
Arterburn, D. E., Crane, P. K., & Veenstra, D. L. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.9.994 · Cited by 255 · see citing works
Ristic, S., Byiers, S., Foley, J. E., & Holmes, D. (2005) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2005.00539.x · Cited by 248 · see citing works
Cellular Mechanism of Action of Metformin
Klip, A., & Leiter, L. A. (1990) · Diabetes Care · doi:10.2337/diacare.13.6.696 · Cited by 238 · see citing works
Jonker, J. W., Wagenaar, E., Mol, C. A. A. M., Buitelaar, M., Koepsell, H., Smit, J. W., & Schinkel, A. H. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.16.5471-5477.2001 · Cited by 227 · see citing works
Weekly Subcutaneous Pegylated Recombinant Native Human Leptin (PEG-OB) Administration in Obese Men
Hukshorn, C. J., Saris, W. H. M., Westerterp-Plantenga, M. S., Farid, A. R., Smith, F. J., & Campfield, L. A. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.11.6955 · Cited by 220 · see citing works
Winckler, W., Weedon, M. N., Graham, R., McCarroll, S. A., Purcell, S., Almgren, P., Tuomilehto, J., Gaudet, D., Boström, K. B., Walker, M., et al. (2007) · Diabetes · doi:10.2337/db06-0202 · Cited by 201 · see citing works
Vella, A. V., Bock, G., Giesler, P. D., Burton, D. B., Serra, D. B., Ligueros‐Saylan, M., Dunning, B. E., Foley, J. E., Rizza, R. A., & Camilleri, M. (2007) · Diabetes · doi:10.2337/db07-0136 · Cited by 200 · see citing works
Self-citationStatistical false positive or true disease pathway?
Todd, J. A. (2006) · Nature Genetics · doi:10.1038/ng0706-731 · Cited by 178 · see citing works
Gloyn, A. L., Hashim, Y., Ashcroft, S. J. H., Ashfield, R., Wiltshire, S., & Turner, R. C. (2001) · Diabetic Medicine · doi:10.1046/j.1464-5491.2001.00449.x · Cited by 170 · see citing works
Kim, H. J., Camilleri, M., Carlson, P., Cremonini, F., Ferber, I., Stephens, D., Mckinzie, S., Zinsmeister, A., & Urrutia, R. (2004) · Gut · doi:10.1136/gut.2003.030882 · Cited by 168 · see citing works
Self-citationHumphries, S. E., Gable, D. R., Cooper, J. A., Ireland, H., Stephens, J. W., Hurel, S. J., Li, K., Palmen, J., Miller, M. A., Cappuccio, F. P., et al. (2006) · Journal of Molecular Medicine · doi:10.1007/s00109-006-0108-7 · Cited by 165 · see citing works
Long-term weight control study: Conclusions
WEINTRAUB, M. I. (1992) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1992.76 · Cited by 161 · see citing works
Sesti, G., Laratta, E., Cardellini, M., Andreozzi, F., Guerra, S. D., Irace, C., Gnasso, A., Grupillo, M., Lauro, R., Hribal, M. L., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2323 · Cited by 157 · see citing works
Genetic determinants of statin intolerance
Oh, J., Ban, M. R., Miskie, B. A., Pollex, R. L., & Hegele, R. A. (2007) · Lipids in Health and Disease · doi:10.1186/1476-511x-6-7 · Cited by 153 · see citing works
Genetic Prediction of Future Type 2 Diabetes
Lyssenko, V., Almgren, P., Anevski, D., Orho‐Melander, M., Sjögren, M., Saloranta, C., Tuomi, T., Groop, L., & the Botnia Study Group (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020345 · Cited by 144 · see citing works
Hegele, R. A., JOY, T. R., Al-Attar, S. A., & Rutt, B. K. (2007) · Journal of Lipid Research · doi:10.1194/jlr.r700004-jlr200 · Cited by 141 · see citing works
Florez, J. C., Jablonski, K. A., Sun, M. W., Bayley, N., Kahn, S. E., Shamoon, H., Hamman, R. F., Knowler, W. C., Nathan, D. M., & Altshuler, D. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2275 · Cited by 131 · see citing works
Florez, J. C., Jablonski, K. A., Kahn, S. E., Franks, P. W., Dabelea, D., Hamman, R. F., Knowler, W. C., Nathan, D. M., & Altshuler, D. (2007) · Diabetes · doi:10.2337/db06-0966 · Cited by 119 · see citing works
Hattersley, A. T., & Pearson, E. R. (2006) · Endocrinology · doi:10.1210/en.2006-0152 · Cited by 118 · see citing works
Hauner, H., Meier, M., ckel, K.-H. J., Frey, U. H., & Siffert, W. (2003) · Pharmacogenetics · doi:10.1097/00008571-200308000-00003 · Cited by 115 · see citing works
Drucker, D. J. (2001) · Current Pharmaceutical Design · doi:10.2174/1381612013397401 · Cited by 113 · see citing works
Blüher, M., Lübben, G., & Paschke, R. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.825 · Cited by 109 · see citing works
A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness
Beinborn, M., Worrall, C. I., McBride, E. W., & Kopin, A. S. (2005) · Regulatory Peptides · doi:10.1016/j.regpep.2005.05.001 · Cited by 99 · see citing works
Snitker, S., Watanabe, R. M., Ani, I., Xiang, A. H., Marroquin, A., Ochoa, C., Goico, J., Shuldiner, A. R., & Buchanan, T. A. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1365 · Cited by 82 · see citing works
Testing of diabetes-associated WFS1 polymorphisms in the Diabetes Prevention Program
Florez, J. C., Jablonski, K. A., McAteer, J. B., Sandhu, M. S., Wareham, N. J., Barroso, I., Franks, P. W., Altshuler, D., & Knowler, W. C. (2007) · Diabetologia · doi:10.1007/s00125-007-0891-x · Cited by 70 · see citing works
Sequence Variation inPPARGMay Underlie Differential Response to Troglitazone
DiStefano, J. K., Yeatts, K. A., Dhanjal, S. K., Black, M. H., Xiang, A. H., Buchanan, T. A., & Watanabe, R. M. (2005) · Diabetes · doi:10.2337/diabetes.54.11.3319 · Cited by 64 · see citing works
Hansen, S. K., Nielsen, E.-M. D., Ek, J., Andersen, G., Glümer, C., Carstensen, B., Mouritzen, P., Drivsholm, T., Borch‐Johnsen, K., Jørgensen, T., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1942 · Cited by 61 · see citing works
A fat attack occurred in fat city
Luft, F. C. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-005-0725-6 · Cited by 53 · see citing works
McClure, D. L., Valuck, R. J., Glanz, M., & Hokanson, J. E. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1341 · Cited by 52 · see citing works
Winkelmann, B. R., Hoffmann, M. M., Nauck, M., Kumar, A., Nandabalan, K., Judson, R., Boehm, B. O., Tall, A. R., Ruaño, G., & März, W. (2003) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500195 · Cited by 51 · see citing works
IL2RA/CD25 polymorphisms contribute to multiple sclerosis susceptibility
Matesanz, F., Caro‐Maldonado, A., Fedetz, M., Fernández, Ó., Milne, R. L., Guerrero, M., Delgado, C., & Alcina, A. (2007) · Journal of Neurology · doi:10.1007/s00415-006-0416-4 · Cited by 50 · see citing works
Molecular genetics goes to the diabetes clinic
Hattersley, A. T. (2005) · Clinical Medicine · doi:10.7861/clinmedicine.5-5-476 · Cited by 48 · see citing works
Phenylethanolamine N‐Methyltransferase G‐148A Genetic Variant and Weight Loss in Obese Women
Peters, W. R., Macmurry, J. P., Walker, J., Giese, R. J., & Comings, D. E. (2003) · Obesity Research · doi:10.1038/oby.2003.56 · Cited by 37 · see citing works
Characterization and Significance of Sulfonylurea Receptors
Siconolfi-Baez, L., Banerji, M. A., & Lebovitz, H. E. (1990) · Diabetes Care · doi:10.2337/diacare.13.3.2 · Cited by 36 · see citing works
Roque, M. I. V., Camilleri, M., Clark, M. M., TePoel, D. A., Jensen, M. D., Graszer, K. M., Kalsy, S. A., Burton, D. D., Baxter, K. L., & Zinsmeister, A. R. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2007.02.037 · Cited by 35 · see citing works
Self-citationWilke, R. A., Berg, R. L., Vidaillet, H. J., Jr., Caldwell, M. D., Burmester, J. K., & Hillman, M. A. (2005) · Clinical Medicine & Research · doi:10.3121/cmr.3.4.207 · Cited by 30 · see citing works
Tremelling, M., & Parkes, M. (2007) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20239 · Cited by 15 · see citing works
Camilleri, M. (2007) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2007.00961.x · Cited by 13 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Stöger, R. J. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.12.1851 · Cited by 78 · see citing works
A model of GLP-1 action on insulin secretion in nondiabetic subjects
Dalla Man, C., Micheletto, F., Sathananthan, A., Rizza, R. A., Vella, A., & Cobelli, C. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00705.2009 · Cited by 45 · see citing works
Self-citationSmushkin, G., & Vella, A. V. (2010) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e32833a558d · Cited by 41 · see citing works
Self-citationIntegrating epigenomics into pharmacogenomic studies
Zhang, W., Dolan, & Huang (2008) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s4341 · Cited by 33 · see citing works
Khabour, O. F., Alzoubi, K. H., Al-Azzam, S. I., & Mhaidat, N. M. (2013) · Genetics and Molecular Research · doi:10.4238/2013.march.13.9 · Cited by 21 · see citing works
Zhang, Y.-P., Zhang, Y.-Y., & Duan, D. D. (2016) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2016.02.003 · Cited by 17 · see citing works
Bazzazzadehgan, S., Shariat‐Madar, Z., & Mahdi, F. (2025) · Biomolecules · doi:10.3390/biom15030414 · Cited by 18 · see citing works
Jayabal, D., Jayanthi, S., Thirumalaisamy, R., & Shimu, M. S. S. (2023) · Journal of Molecular Modeling · doi:10.1007/s00894-023-05616-2 · Cited by 9 · see citing works
Interface between Pharmacotherapy and Genes in Human Obesity
O’Connor, A., & Swick, A. G. (2013) · Human Heredity · doi:10.1159/000349975 · Cited by 8 · see citing works
Cell-based Models for Discovery of Pharmacogenomic Markers of Anticancer Agent Toxicity.
Zhang, W., Huang, R. S., & Dolan, M. E. (2008) · PubMed · Cited by 8 · see citing works
AC3: A Novel Gene Plays a Role in the Regulation of Body Weight
Gu, H. F. (2010) · The Open Diabetes Journal · doi:10.2174/1876524601003010011 · Cited by 5 · see citing works
Shokrani, B., Brim, H., Hydari, T., Afsari, A., Lee, E., Nouraie, M. S., Sherif, Z. A., & Ashktorab, H. (2020) · BMC Gastroenterology · doi:10.1186/s12876-020-01412-x · Cited by 5 · see citing works
The Future Directions of Childhood Obesity and Clinical Management
O’Gorman, C. S., Scully, P., O’Sullivan, D. M., Cauchi, J., Daneman, D., & Hamilton, J. K. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812840-4.00034-7 · Cited by 1 · see citing works
The Future Directions and Clinical Management of Childhood Obesity
O’Gorman, C. S., Cauchi, J., Hamilton, J. K., & Daneman, D. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374995-6.10047-7
Impact of Candidate Genes on Obesity and Type 2 Diabetes
Långberg, E. (2011) · Figshare
Micheletto, F. (2013) · Padua@research (University of Padova)
(2009) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32833118e2
- Authors
- Vella, A., & Camilleri, M.
- Affiliations
- Mayo Clinic (US)
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa Healthcare
- Published
- 2008-04-21
- Volume
- 9
- Issue
- 7
- Pages
- 1109-1119
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- PMC
- PMC3901565
- OpenAlex
- W2170397385
- Cited by
- 17
- References
- 86
- Citations by year
- 2025: 1 · 2023: 1 · 2020: 1 · 2019: 1 · 2016: 1 · 2013: 3
- FWCI
- 2.73
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Expert Opinion on Pharmacotherapy (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (DK67071, DK-02638, P01DK068055, K24DK002638, R01DK078646)
- National Center for Research Resources (RR-024150, UL1RR024150)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Nutrition, Genetics, and Disease
- Keywords
- pharmacogenetics, diabetes mellitus, obesity, type 1 diabetes, type 2 diabetes, common genetic variants, genetic susceptibility, drug response, candidate genes, metabolic disorders, personalized medicine, genetic association studies
- MeSH terms
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Humans, Obesity, Pharmacogenetics, Biomarkers, Controlled Clinical Trials as Topic, Genetic Predisposition to Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
